Ozempic nausea symptom guide

Ozempic nausea: current label rates and warning signs

Review nausea during Ozempic care using current injection and tablet labeling, including product-specific trial rates, vomiting and dehydration questions, medication review, and compounded-product distinctions.

Educational guideUpdated August 13, 2026

A product-first nausea check during Ozempic care

Identify the exact product and route: Ozempic weekly injection, Ozempic daily tablets, another semaglutide product, or a patient-specific compounded prescription.

Describe queasiness separately from vomiting, reflux, early fullness, bloating, diarrhea, constipation, and severe or persistent abdominal pain.

Record onset, duration, severity, food and fluid intake, urine output, glucose readings when relevant, and timing relative to treatment, a clinician-directed change, refill, illness, or another medicine.

Contact the prescriber before changing Ozempic or adding an anti-nausea medicine; follow individualized food, fluid, glucose, and medication instructions.

Use prompt in-person care for severe abdominal, dehydration, bleeding, allergic, neurologic, or other emergency warning signs.

Direct answer

Nausea is a common adverse reaction with Ozempic, but rates depend on the formulation and study. In pooled placebo-controlled trials of Ozempic weekly injection, nausea occurred in 15.8% with 0.5 mg and 20.3% with 1 mg, versus 6.1% with placebo. The current combined Ozempic and Rybelsus tablet label reports nausea in 11% with semaglutide 7 mg and 20% with 14 mg, versus 6% with placebo; those tablet trial strengths do not establish a rate for every current Ozempic tablet strength. Contact the prescriber for nausea that persists, worsens, recurs, limits food or fluids, or occurs with vomiting. Severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, confusion, jaundice, trouble breathing, or facial or throat swelling needs prompt in-person assessment.

Current injection-label answer

Ozempic injection trials report separate nausea rates by strength

The current Novo Nordisk Ozempic injection label, effective June 1, 2026, lists nausea among the most common adverse reactions. In two pooled placebo-controlled trials in adults with type 2 diabetes, nausea was reported in 15.8% of participants receiving Ozempic 0.5 mg and 20.3% receiving Ozempic 1 mg, versus 6.1% receiving placebo. The label says most nausea, vomiting, and diarrhea reports occurred during dose escalation. These group-level findings do not predict one person’s cause, severity, or duration.

Keep each percentage tied to its labeled study group: Ozempic 0.5 mg, Ozempic 1 mg, or placebo.
Do not average the strength groups, transfer a Wegovy weight-management rate, or present one value as a universal Ozempic nausea rate.
Timing during escalation can support a treatment review, but it does not prove Ozempic caused every episode or establish how long symptoms should last.

Tablet evidence boundary

Current Ozempic tablet strengths and the published safety table use different strength systems

The current combined Ozempic and Rybelsus tablet label, effective January 30, 2026, covers once-daily oral semaglutide. Its displayed placebo-controlled trial table reports nausea in 11% with semaglutide tablets 7 mg and 20% with 14 mg, versus 6% with placebo. The label explains that safety for current Ozempic 1.5 mg, 4 mg, and 9 mg tablets is established from the oral-semaglutide program. The table therefore confirms nausea as a recognized tablet adverse reaction, but it is not a strength-specific rate table for every current Ozempic tablet presentation.

Confirm whether the prescription is Ozempic injection or Ozempic tablets before interpreting a rate or administration routine.
Do not treat the 7 mg or 14 mg trial percentages as current 1.5 mg, 4 mg, or 9 mg Ozempic tablet strength-specific rates.
Do not transfer injection timing, missed-dose, storage, or trial-rate instructions to tablets, or tablet routines to an injection.

Vomiting, hydration, and glucose

Poor intake or repeated vomiting changes the urgency of nausea

Current Ozempic injection and tablet labeling warns that diarrhea, nausea, and vomiting can cause dehydration and kidney problems. Hypoglycemia risk can also increase when semaglutide is used with insulin or an insulin secretagogue such as a sulfonylurea. Nausea alone does not diagnose dehydration, kidney injury, or low blood sugar, so the responsible clinician needs the full symptom, intake, medication, and monitoring pattern.

Share vomiting or diarrhea frequency, ability to keep fluids down, urine amount and color, dizziness, fainting, weakness, heat exposure, kidney history, recent illness, and blood-pressure or diuretic medicines.
If glucose monitoring is part of care, record readings with symptoms, meals, activity, alcohol, insulin, sulfonylureas, and other glucose-lowering medicines; follow the individualized response plan.
Do not improvise a medicine hold, extra or catch-up dose, electrolyte recipe, anti-nausea medicine, or glucose treatment from a forum post.

Symptom pattern and escalation

Expected-side-effect assumptions can hide a different urgent problem

Nausea means queasiness or feeling as though vomiting may occur; it is not interchangeable with vomiting, reflux, severe stomach pain, abdominal swelling, or jaundice. Infection, pregnancy, migraine, gallbladder or pancreatic disease, obstruction, severe gastroparesis, another medicine, or another condition can require a different response. The Ozempic labels advise prompt contact for nausea, vomiting, or diarrhea that does not go away and for severe or persistent stomach problems.

Contact the prescriber for new, persistent, worsening, recurrent, or function-limiting nausea; vomiting; poor intake; markedly reduced urination; dizziness; or symptoms after a refill or clinician-directed change.
Seek prompt in-person assessment for severe or persistent abdominal pain, pain spreading to the back, repeated vomiting, inability to keep fluids down, fainting, confusion, severe weakness, jaundice, blood or coffee-ground material in vomit, black stools, or chest pain.
Trouble breathing, facial or throat swelling, widespread hives with breathing difficulty, collapse, or another serious allergic pattern needs emergency evaluation.

Product and medication review

Ozempic evidence does not establish a compounded-semaglutide nausea rate

Ozempic injection and Ozempic tablets are FDA-approved finished semaglutide products for product-specific type 2 diabetes indications; Ozempic is not the semaglutide brand labeled for chronic weight management. A patient-specific compounded semaglutide preparation is not FDA-approved Ozempic or an FDA-approved generic Ozempic finished product and may differ in concentration, inactive ingredients, container, labeling, storage, and beyond-use date. The prescriber should verify the exact product and review other possible contributors before the next treatment decision.

Bring the product name, route, strength or concentration, manufacturer or dispensing pharmacy, refill or lot details, storage history, and a photo of the current label.
List insulin, sulfonylureas, metformin, SGLT2 inhibitors, diuretics, pain medicines, antibiotics, alcohol, cannabis, vitamins, minerals, supplements, and any recent medicine change.
Do not skip, repeat, stop, restart, split, increase, decrease, switch, or convert Ozempic based on generic nausea advice, and avoid research-use products, counterfeit products, unlabeled vials, or no-prescription sellers.

Patient safety checklist

Questions to ask about nausea during Ozempic care

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Which exact product and route am I using: Ozempic injection, Ozempic tablets, another semaglutide product, or a patient-specific compounded prescription?

✓

When did nausea begin, how long does it last, how severe is it, and did it follow treatment, a clinician-directed change, refill, illness, travel, or another medicine?

✓

Can I keep food and fluids down, how often am I vomiting or having diarrhea, how much am I urinating, and do I feel dizzy, faint, weak, constipated, or unusually full?

✓

Do I have severe or persistent abdominal pain, pain spreading to the back, fever, jaundice, abdominal swelling, blood in vomit, black stools, rash, or swelling?

✓

Do insulin, sulfonylureas, SGLT2 inhibitors, metformin, diuretics, blood-pressure medicines, pain medicines, antibiotics, alcohol, cannabis, vitamins, or supplements change the review?

✓

If glucose or blood-pressure monitoring is part of care, which readings and symptoms should trigger same-day guidance or urgent assessment?

✓

Should the product label, pharmacy, refill or lot, storage history, concentration, route, or inactive ingredients be reviewed before the next treatment decision?

✓

Who should I contact before the next treatment or refill, and which symptoms should bypass messaging for urgent or emergency care?

FAQs

Short answers for patients

Does Ozempic cause nausea?

Nausea is a recognized common adverse reaction in current Ozempic injection and tablet labeling. A label association does not prove Ozempic caused one person’s nausea, so formulation, timing, severity, intake, vomiting, other medicines, and warning signs still need review.

How common is nausea with Ozempic injection?

In pooled placebo-controlled trials in adults with type 2 diabetes, nausea occurred in 15.8% with Ozempic 0.5 mg and 20.3% with Ozempic 1 mg, versus 6.1% with placebo. Keep those percentages tied to the studied injection groups rather than combining them into one rate.

How common is nausea with Ozempic tablets?

The current combined tablet label displays nausea rates of 11% with semaglutide 7 mg and 20% with 14 mg, versus 6% with placebo. Those trial strengths support nausea as a recognized tablet adverse reaction but do not establish separate rates for every current Ozempic tablet strength.

How long does Ozempic nausea last?

The current labels do not provide one expected duration. Most nausea, vomiting, and diarrhea reports in the pooled injection trials occurred during dose escalation, but that does not predict an individual timeline. Contact the prescriber for persistent, severe, recurrent, worsening, or intake-limiting symptoms.

What can I eat for Ozempic nausea?

There is no single meal plan that is safe or effective for everyone. Ask the responsible clinician or dietitian for individualized guidance based on vomiting, hydration, diabetes medicines, glucose readings, kidney or heart conditions, pregnancy possibility, allergies, and nutrition needs. Inability to keep food or fluids down needs prompt assessment.

Can I take an anti-nausea medicine with Ozempic?

Ask the responsible clinician or pharmacist before adding an anti-nausea medicine. The possible cause, pregnancy, heart-rhythm risk, sedation, constipation, other medicines, and the exact Ozempic formulation can affect whether a proposed treatment is appropriate.

Should I skip Ozempic if I feel nauseated?

Do not skip, repeat, stop, restart, split, or change Ozempic based on generic online advice. Contact the responsible prescriber with the symptom pattern and product details before the next treatment decision. Urgent warning signs require in-person assessment.

Does Ozempic nausea guidance apply to compounded semaglutide?

Not automatically. A patient-specific compounded preparation is not FDA-approved Ozempic and may differ in concentration, inactive ingredients, presentation, labeling, storage, and beyond-use date. Ozempic trial rates do not establish a nausea incidence for a compounded preparation.

When is nausea during Ozempic care urgent?

Seek prompt in-person care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, fainting, confusion, markedly reduced urination, severe weakness, jaundice, blood or coffee-ground material in vomit, black stools, trouble breathing, facial or throat swelling, or another serious allergic pattern.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Novo Nordisk OZEMPIC injection prescribing information — effective June 1, 2026 DailyMed: Novo Nordisk OZEMPIC and RYBELSUS tablet prescribing information — effective January 30, 2026 MedlinePlus: Semaglutide injection drug information MedlinePlus: Nausea and vomiting MedlinePlus: Dehydration Peptide12: Ozempic Peptide12: Compounded semaglutide injection Peptide12: Ozempic injection side effects Peptide12: Ozempic and dehydration Peptide12: Semaglutide nausea Peptide12: GLP-1 nausea and vomiting Peptide12: Ozempic constipation Peptide12: When to message your clinician Peptide12: How online peptide therapy works